Bunkerhill Abdominal Aortic Quantification (AAQ) vs ASSURE Wearable ECG

Tool B (ASSURE Wearable ECG) emphasizes patient usability with its comfortable, non-adhesive SensorFit Garment and mobile application, designed for continuous wear and ease of use for patients. While Tool A (Bunkerhill AAQ) focuses on streamlining clinician workflows through EHR integration and a conversational AI interface, Tool B's design prioritizes both patient comfort and intuitive clinician review via its dedicated platform.

Tool A (Bunkerhill AAQ) offers significant proactive clinical value by being the first FDA-cleared AI to automate abdominal aortic diameter quantification on routine CT scans, enabling early aneurysm detection and streamlined follow-up for a broad patient population. Its broader Carebricks platform also identifies other cardiovascular risks from routine CTs, leading to earlier intervention for previously overlooked conditions. Tool B (ASSURE Wearable ECG) provides continuous monitoring and has demonstrated strong safety and effectiveness in managing already at-risk cardiac patients, but Tool A's ability to opportunistically screen and identify new at-risk patients from existing data gives it a broader proactive impact.

Both Tool A (Bunkerhill AAQ) and Tool B (ASSURE Wearable ECG) require direct contact for pricing, indicating a lack of public transparency regarding their cost structures. Without specific pricing models or publicly available return on investment (ROI) data for either product, it is not possible to definitively determine which offers better value.

Tool A (Bunkerhill AAQ) demonstrates superior enterprise readiness through its seamless integration with EHRs, cloud-based deployment on AWS, and broad adoption across numerous major health systems like UTMB Health, Cleveland Clinic, and Mayo Clinic. It also has established CMS reimbursement pathways for its AI cardiovascular analysis. While Tool B (ASSURE Wearable ECG) is also FDA-cleared and HIPAA compliant, Tool A's extensive deployment across diverse clinical and operational workflows within large health systems, coupled with a reimbursement pathway, indicates a more mature and integrated enterprise solution.

Tool A (Bunkerhill AAQ) showcases a more foundational innovation with its pioneering FDA clearances for AI-driven quantification and detection on both contrast and non-contrast routine CTs. Its underlying 'generative AI platform for clinical reasoning and action' allows health systems to rapidly build and deploy diverse custom AI agents, redefining how AI is adopted in healthcare. While Tool B (ASSURE Wearable ECG) features innovative wearable hardware and advanced signal processing algorithms, Bunkerhill's platform approach offers broader, more adaptable AI innovation.

Tool B (ASSURE Wearable ECG) provides clear and accessible support channels, including a 24/7 toll-free helpline for both patients and providers, a Patient FAQ, and detailed patient handbooks and application user manuals. In contrast, Tool A (Bunkerhill AAQ) offers limited public information regarding its customer support and documentation, primarily directing users to contact them for demos or general inquiries.